Which generation of drugs does Pazopanib (Pazopanib) targeted drug belong to?

Pazopanib (also known as Pazopanib) is a targeted therapy drug classified as a first-generation multi-target tyrosine kinase inhibitor (TKI). It mainly inhibits a variety of receptor tyrosine kinases involved in tumor angiogenesis and tumor cell proliferation, such as VEGFR (vascular endothelial growth factor receptor) 1-3< span>, PDGFR (platelet-derived growth factor receptor) and c-Kit, etc., thereby inhibiting tumor growth and spread. This type of multi-target TKI is of great significance in the early stages of tumor treatment and provides new treatment ideas for patients with advanced cancer.

As the first generationTKI, pazopanib’s advantage lies in its broad target coverage and its inhibitory effect on multiple receptors. This mechanism is particularly applicable to tumor types like renal cancer and soft tissue sarcoma, as these tumors often rely on angiogenesis to sustain growth. Pazopanib was approved by China in 2012 for the treatment of advanced renal cell carcinoma (RCC) and certain types of soft tissue sarcomas, filling the gap in the lack of effective treatments for some advanced patients.

Although the first generationTKIs such as pazopanib have achieved remarkable results in clinical treatment, due to their non-selective targeting properties, they often cause a series of side effects, such as hypertension, abnormal liver function, hand-foot syndrome, etc. Therefore, in the subsequent development of targeted drugs, researchers continue to develop second- and third-generation TKIs. These newer-generation drugs usually have greater selectivity, less toxic side effects, or can overcome drug-resistant mutations.

Nonetheless, as a first-generation TKI, pazopanib still plays an important role in multiple indications, especially for patients who are resistant or intolerant to other TKIs. In the future, with the development of more precision treatment strategies, the use of pazopanib may become more individualized and adjusted according to the patient's specific genetic background and resistance mechanism to achieve better therapeutic effects.

References：https://www.votrient.com/